[Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
Human recombinant erythropoietin has been administered to 6 children with uremic anaemia in the course of end stage renal disease, treated with CAPD. The drug has been injected subcutaneously in the dose of 2,000 U twice a week, until hematocrit and hemoglobin values equivalent to 30% and 9-10 g/dL have been achieved. A decrease in cytotoxic antibodies titre has been noted during a 6-month follow-up. No serious adverse reactions have been seen.
Litwin
M
M
Oddziału Dializoterapii i Transpalntacji Nerek Centrum Zdrowia Dziecka.
Boguszewska-Baczkowska
A
A
Jelonek
A
A
D000293:Adolescent; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D002648:Child; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins; D014511:Uremia / Q000150:complications
D011994:Recombinant Proteins; D004921:Erythropoietin
Ludzka erytropoetyna rekombinowana w leczeniu niedokrwistości mocznicowej u dzieci dializowanych metoda ciagłej ambulatoryjnej dializy otrzewnowej.